Results 311 to 320 of about 259,118 (384)

Translating cardiovascular ion channel and Ca2+ signalling mechanisms into therapeutic insights

The Journal of Physiology, EarlyView.
Abstract figure legend This white paper integrates mechanistic discoveries across ion channel biology, Ca2+ signalling and multiscale cardiovascular physiology to highlight new opportunities for accelerating research and guiding next‐generation therapies.
Silvia Marchianò, Miguel Martín‐Aragón Baudel, Charlotte E. R. Smith, Gonzalo Hernandez Hernandez, Donald M. Bers, Patrick M. Boyle, Dobromir Dobrev, Shanna Hamilton, Osama F. Harraz, Na Li, Thomas A. Longden, William E. Louch, Madeline Nieves‐Cintron, Matthew A. Nystoriak, Walter Lee Murfee, Przemysław B. Radwański, Swapnil K. Sonkusare, Manuel F. Navedo, Eleonora Grandi   +18 more
wiley   +1 more source

The impact of renin-angiotensin system inhibitors on colorectal neoplasm development. [PDF]

Clin Hypertens
Han YM, Choi JM, Rhee TM, Choi SY, Lee H.   +4 more
europepmc   +1 more source

Fenofibrate (peroxisome proliferator-activated receptor alpha agonist) modulates the renin-angiotensin system in the heart of mice fed with a high-fat diet

, 2012
Thiago da Silva Torres
openalex   +1 more source

Identification of Crucial Drug Targets and Pathways to Reprogram Drug Resistance Through Epigenetic Modulation in Advanced Lung Cancer Using Integrated Bioinformatics Approach

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Resistance to chemotherapy, which is demonstrated in almost every patient with advanced‐stage lung cancer (ALC), underscores an urgent need to unravel the underlying molecular mechanisms and identify novel strategies to overcome drug resistance. In the present study, an attempt was made to identify epigenetic targets and modulators that can be
Okibur Rahman, Mossammat Rima Akter, Nur Alam   +2 more
wiley   +1 more source

Combination of cyclin-dependent kinase 4/6 inhibitors and renin-angiotensin system inhibitors in breast cancer treatment: a promising therapeutic approach. [PDF]

Rev Assoc Med Bras (1992)
Mutlu E, İnanç M.
europepmc   +1 more source

ClC‐2 Contributes to Hypotonicity‐Induced Adrenal Aldosterone Secretion

Acta Physiologica, Volume 242, Issue 3, March 2026.
ABSTRACT Aim The zona glomerulosa (ZG) of the adrenal cortex regulates blood pressure and electrolyte homeostasis through aldosterone production. In ZG cells, potassium and angiotensin II (Ang II) trigger calcium oscillations that drive aldosterone synthesis.
Marina Volkert, Hoang An Dinh, Ute I. Scholl, Gabriel Stölting   +3 more
wiley   +1 more source

Retraction: Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. [PDF]

Front Pharmacol
Frontiers Editorial Office.
europepmc   +1 more source

Albuminuria Predicts a Rapid Decline in Kidney Function in 2 International, Longitudinal Cohorts of Adults With Sickle Cell Anemia

American Journal of Hematology, Volume 101, Issue 2, Page 304-310, February 2026.
ABSTRACT Chronic kidney disease (CKD) is common and a major contributor to increased morbidity and early mortality in people with sickle cell anemia (SCA). Urine albumin‐to‐creatinine ratio (uACR) is recommended to identify patients with SCA‐related CKD but its utility in predicting long‐term kidney dysfunction remains unclear in this patient ...
Pablo Bartolucci, Étienne Audureau, Vincent Audard, Frédéric Galactéros, Guillaume Lettre, Charmaine Anthony, Olufolake Egbujo, Jin Han, Maria Armila Ruiz, James P. Lash, Victor R. Gordeuk, Xu Zhang, Santosh L. Saraf   +12 more
wiley   +1 more source

Propofol exerted the neuroprotective effects by regulating renin-angiotensin system and mitochondria-associated endoplasmic reticulum membrane in the postoperative cognitive dysfunction. [PDF]

BMC Anesthesiol
Ding W, Zheng Y, Li X, Lv H, Zhang J, Chen W.   +5 more
europepmc   +1 more source

An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 579-588, February 2026.
Aims Glucagon‐like peptide‐1 (GLP‐1) and glucagon dual receptor agonists are in clinical development for a range of metabolic conditions, including type 2 diabetes and obesity. The cardiovascular actions at these receptors are well studied, but less is known about their combination.
James Goodman, Victoria E. Parker, Carmel M. McEniery, Giovanni Di Stefano, Annette Hubsch, Evangelia Vamvaka, Jo Helmy, Fotini Kaloyirou, Navazh Jalaludeen, Peter Barker, Lutz Jermutus, Joseph Cheriyan, Philip Ambery, Ian B. Wilkinson   +13 more
wiley   +1 more source